Liquidia Corporation (LQDA) stock surged +12.91%, trading at $35.86 on NASDAQ, up from the previous close of $31.76. The stock opened at $31.76, fluctuating between $29.45 and $38.16 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jan 09, 2026 | 31.76 | 38.16 | 29.41 | 35.86 | 7.98M |
| Jan 08, 2026 | 30.77 | 32.33 | 30.35 | 31.76 | 1.1M |
| Jan 07, 2026 | 31.19 | 31.60 | 30.25 | 30.99 | 1.53M |
| Jan 06, 2026 | 31.89 | 31.92 | 29.30 | 30.72 | 1.91M |
| Jan 05, 2026 | 31.36 | 32.55 | 30.28 | 32.15 | 1.73M |
| Jan 02, 2026 | 34.54 | 34.88 | 30.76 | 31.40 | 2.88M |
| Dec 31, 2025 | 34.13 | 35.20 | 33.92 | 34.49 | 904.81K |
| Dec 30, 2025 | 34.76 | 35.03 | 34.09 | 34.43 | 1.01M |
| Dec 29, 2025 | 34.28 | 35.24 | 34.28 | 34.75 | 813.51K |
| Dec 26, 2025 | 36.24 | 36.24 | 34.37 | 34.41 | 667.16K |
| Dec 24, 2025 | 35.41 | 36.41 | 35.13 | 35.79 | 409.53K |
| Dec 23, 2025 | 35.60 | 36.09 | 35.06 | 35.24 | 627.38K |
| Dec 22, 2025 | 35.24 | 36.11 | 34.60 | 35.78 | 950.82K |
| Dec 19, 2025 | 33.63 | 35.17 | 33.63 | 34.53 | 1.77M |
| Dec 17, 2025 | 35.03 | 35.26 | 33.95 | 34.03 | 910.06K |
| Dec 16, 2025 | 33.94 | 35.40 | 33.63 | 35.26 | 1.35M |
| Dec 15, 2025 | 33.66 | 34.68 | 33.51 | 34.19 | 1.01M |
| Dec 12, 2025 | 32.71 | 33.75 | 32.65 | 33.38 | 919.78K |
| Dec 11, 2025 | 32.68 | 33.48 | 32.11 | 32.59 | 930.18K |
| Dec 10, 2025 | 33.90 | 34.55 | 32.40 | 32.68 | 1.52M |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
| Employees | 170 |
| Beta | 0.49 |
| Sales or Revenue | $17.49M |
| 5Y Sales Change% | -0.288% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep